OTCMKTS:CPHRF

Cipher Pharmaceuticals Stock Forecast, Price & News

$1.34
-0.10 (-6.94 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.34
$1.38
50-Day Range
$1.03
$1.44
52-Week Range
$0.60
$1.51
Volume2,050 shs
Average Volume11,865 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CPHRF News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products also include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.17 out of 5 stars

Medical Sector

1007th out of 2,100 stocks

Drug Manufacturers - Specialty & Generic Industry

15th out of 60 stocks

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Cipher Pharmaceuticals (OTCMKTS:CPHRF) Frequently Asked Questions

Is Cipher Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cipher Pharmaceuticals stock.
View analyst ratings for Cipher Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Cipher Pharmaceuticals?

Wall Street analysts have given Cipher Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cipher Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cipher Pharmaceuticals?

Cipher Pharmaceuticals saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 22,300 shares, an increase of 457.5% from the May 13th total of 4,000 shares. Based on an average daily trading volume, of 3,200 shares, the days-to-cover ratio is presently 7.0 days.
View Cipher Pharmaceuticals' Short Interest
.

When is Cipher Pharmaceuticals' next earnings date?

Cipher Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Cipher Pharmaceuticals
.

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) issued its quarterly earnings data on Thursday, May, 5th. The company reported ($0.10) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.06. The business earned $9.10 million during the quarter, compared to analyst estimates of $10.87 million.
View Cipher Pharmaceuticals' earnings history
.

How has Cipher Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Cipher Pharmaceuticals' stock was trading at $0.6097 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CPHRF stock has increased by 119.8% and is now trading at $1.34.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CPHRF?

3 equities research analysts have issued 12-month target prices for Cipher Pharmaceuticals' stock. Their forecasts range from $0.95 to $3.00. On average, they anticipate Cipher Pharmaceuticals' stock price to reach $1.98 in the next year. This suggests a possible upside of 48.0% from the stock's current price.
View analysts' price targets for Cipher Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Cipher Pharmaceuticals' key executives?

Cipher Pharmaceuticals' management team includes the following people:
  • Mr. Craig J. Mull, Interim CEO & Chairman
  • Mr. Scott M. Langille CPA, CMA, MBA, Chief Financial Officer (Age 64, Pay $51.8k)
  • Dr. Diane Gajewczyk, VP of Scientific & Medical Affairs

Who are some of Cipher Pharmaceuticals' key competitors?

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CPHRF."

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPHRF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cipher Pharmaceuticals' stock price today?

One share of CPHRF stock can currently be purchased for approximately $1.34.

How many employees does Cipher Pharmaceuticals have?

Cipher Pharmaceuticals employs 5 workers across the globe.

What is Cipher Pharmaceuticals' official website?

The official website for Cipher Pharmaceuticals is www.cipherpharma.com.

Where are Cipher Pharmaceuticals' headquarters?

Cipher Pharmaceuticals is headquartered at 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada.

How can I contact Cipher Pharmaceuticals?

Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company can be reached via phone at +1-905-6025840.


This page was last updated on 6/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.